12 Health Care Stocks Moving In Friday's After-Market Session

Gainers

• Lixte Biotech Holdings LIXT stock increased by 22.13% to $1.49 during Friday's after-market session. The market value of their outstanding shares is at $20.4 million.
• Quoin Pharmaceuticals QNRX stock rose 14.55% to $3.7. The market value of their outstanding shares is at $30.8 million.
• CohBar CWBR shares moved upwards by 10.15% to $0.5. The company's market cap stands at $43.0 million.
• Bellerophon Therapeutics BLPH stock rose 8.67% to $2.88. The company's market cap stands at $27.3 million.
• Mesoblast MESO stock increased by 8.44% to $5.65. The market value of their outstanding shares is at $731.5 million.
• Myovant Sciences MYOV stock increased by 7.17% to $15.69. Myovant Sciences's trading volume hit 127.3K shares by close, accounting for 21.06% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.4 billion.

Losers

• Omeros OMER shares decreased by 5.68% to $6.48 during Friday's after-market session. The company's market cap stands at $405.2 million.
• Lexicon Pharmaceuticals LXRX shares fell 4.08% to $4.0. This security traded at a volume of 324.7K shares come close, making up 42.98% of its average volume over the last 100 days. The market value of their outstanding shares is at $595.5 million.
• Trevi Therapeutics TRVI stock fell 3.14% to $0.87. The market value of their outstanding shares is at $22.4 million.
• Annovis Bio ANVS stock fell 3.12% to $20.84. The company's market cap stands at $168.8 million.
• Celyad Oncology CYAD stock decreased by 2.98% to $4.56. Today's trading volume for this security ended up closing at 134.7K shares, which is 563.8 percent of its average volume over the last 100 days. The company's market cap stands at $73.3 million.
• AcelRx Pharmaceuticals ACRX shares fell 2.95% to $0.56. The market value of their outstanding shares is at $66.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.